Consensus expectations for Ironwood Pharmaceuticals include Q2 revenue of $118.0 million and EPS of $0.26, with the current $4.46 stock price trading well below the $6.23 average analyst target.
Investors are primarily focused on the commercial execution of LINZESS, specifically monitoring U.S. net sales and prescription demand trends following strategic pricing adjustments.
Additionally, management is expected to provide updates on the Phase 3 STARS-2 trial for apraglutide, a key asset for mitigating the 2029 patent cliff. Reaffirming full-year adjusted EBITDA guidance of over $300 million will be essential to maintain recent positive sentiment.